Hospira Inc. Recalls Opioid Antidote Naloxone
June 7, 2018
Source: Ddu
609
As per the U.S. Food and Drug Administration, Hospira, the manufacturer of the opioid antidote Naloxone, voluntarily recalled the antidote on Monday. The FDA also said the recall happened due to the possibility of "loose particulate matter on the syringe plunger" that could cause numerous health risks.
According to the FDA, if the antidote drugs are used on a patient, they could suffer from “allergic reactions, local irritation” and a wide number of cardiovascular issues, including restriction of blood supply to tissues. The FDA stated that there has not yet been any reports of patient harm from Naloxone.
The two batches with numbers 72680LL and 76510LL in 0.4 mg/mL and 1 mL in 2.5 units mL are subject to the recall which were distributed between February 2017 and February 2018 to the Hospital, wholesalers, in the United States, Puerto Rico, and Guam.
In the statement, Hospira Inc. announced that the wholesalers, distributors, retailers and the hospitals should not use or sell the recalled Naloxone and should alert stores, pharmacies, and clinics who have received it.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- AZ’s Farxiga Gets FDA Priority Review For Heart Failure January 8, 2020
- Global Recall of CyPass Micro-Stent by Alcon September 3, 2018
- Researchers Move Forward In Their Search for Non-Addictive Analgesic August 31, 2018
- Breakthrough Device Designation Granted to Digital Intervention for Alzheimer’s August 27, 2018
- FDA Approved Eye Drop Oxervate to Treat Neurotrophic Keratitis August 27, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
